Diabetes · SGLT2 Inhibitor
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/6/2026, 12:00:40 AM
Assessment confidence: 77% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions. Regulatory context from FDA (FDA TA — DAPAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (10 high-relevance).
Portfolio teams should assess the impact of this submission on market dynamics and consider strategic responses to new entrants. The strongest clinical anchor is STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (ClinicalTrials.gov), entity match (dapagliflozin). In Diabetes · SGLT2 Inhibitor, 8 regulatory and 1 competitive items passed relevance filtering for Jiangsu Hansoh Pharma.
The most relevant competitive pressure comes from FDA Issues Guidance on Postapproval Pregnancy Safety Studies (Humanexa Signals) — moderate corpus alignment. This submission indicates Jiangsu Hansoh's entry into the SGLT2 inhibitor market, potentially increasing competition against established players.
Regulatory risk is concentrated around FDA TA — DAPAGLIFLOZIN (ORIG) (FDA). Entity match (dapagliflozin); Regulatory pathway relevance (nda). The submission is currently under standard review, which could influence the approval timeline and market entry strategies for competitors.
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceFDA AP — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
Raw openFDA evidence
View raw openFDA evidenceSTOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
ClinicalTrials.govhigh relevance
Entity match (dapagliflozin)
FDA document
View sourceA Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 t
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View sourceJanus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNon-Pharmacological Methods in Heel Lance
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Issues Guidance on Postapproval Pregnancy Safety Studies
Humanexa Signalsmedium relevance
Moderate corpus alignment
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSystematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions.
The entry of Jiangsu Hansoh Pharma could lead to increased competition, potentially impacting market share and pricing strategies for existing SGLT2 inhibitors.
The submission is currently under standard review, which could influence the approval timeline and market entry strategies for competitors.
Monitor the review progress and any subsequent approval outcomes for ANDA216119.
Track for follow-up milestones; no immediate action required.